(CRI) Carter’s - Overview
Stock: Childrenswear, Bodysuits, Sleepwear, Denim, Footwear
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 4.42% |
| Yield on Cost 5y | 1.95% |
| Yield CAGR 5y | 2.58% |
| Payout Consistency | 90.8% |
| Payout Ratio | 98.7% |
| Risk 5d forecast | |
|---|---|
| Volatility | 47.4% |
| Relative Tail Risk | -4.06% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.23 |
| Alpha | -43.29 |
| Character TTM | |
|---|---|
| Beta | 1.309 |
| Beta Downside | 0.836 |
| Drawdowns 3y | |
|---|---|
| Max DD | 71.26% |
| CAGR/Max DD | -0.26 |
Description: CRI Carter’s January 17, 2026
Carter’s, Inc. (NYSE:CRI) designs, sources, and markets a portfolio of children’s apparel and related products-including Carter’s, OshKosh B’gosh, Skip Hop, and several licensed brands-across the United States and international markets.
The business is organized into three operating segments: U.S. Retail (company-owned stores and e-commerce), U.S. Wholesale (department stores, national chains, and specialty retailers), and International (wholesale and licensing arrangements).
Product offerings span the full children’s lifecycle: basics such as bodysuits and denim, specialty items like baby furniture and kid-focused accessories, and ancillary categories including footwear, swimwear, toys, and home décor.
Sales are driven through a multichannel mix of brick-and-mortar wholesale partners, over 1,200 Carter’s/OshKosh retail locations, and direct-to-consumer digital platforms (carters.com, oshkosh.com, skiphop.com, and a mobile app).
Key recent metrics (FY 2023): revenue of approximately $4.1 billion, comparable-store sales growth of ~5% YoY in the U.S. Retail segment, and e-commerce contributing roughly 30% of total sales-highlighting the accelerating shift to online channels.
Sector drivers that materially affect performance include U.S. birth-rate trends (a long-term tailwind for children’s apparel), consumer confidence in discretionary spending, and inflation-linked pricing pressure on low-margin apparel categories.
For a deeper quantitative breakdown, the ValueRay platform offers granular financial metrics and peer comparisons worth reviewing.
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income: 89.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA -7.95 > 1.0 |
| NWC/Revenue: 22.31% < 20% (prev 20.67%; Δ 1.65% < -1%) |
| CFO/TA 0.06 > 3% & CFO 151.2m > Net Income 89.1m |
| Net Debt (994.2m) to EBITDA (199.5m): 4.98 < 3 |
| Current Ratio: 2.26 > 1.5 & < 3 |
| Outstanding Shares: last quarter (35.4m) vs 12m ago 0.40% < -2% |
| Gross Margin: 46.79% > 18% (prev 0.48%; Δ 4631 % > 0.5%) |
| Asset Turnover: 116.9% > 50% (prev 119.5%; Δ -2.64% > 0%) |
| Interest Coverage Ratio: 4.66 > 6 (EBITDA TTM 199.5m / Interest Expense TTM 31.0m) |
Altman Z'' 3.79
| A: 0.26 (Total Current Assets 1.13b - Total Current Liabilities 501.7m) / Total Assets 2.47b |
| B: 0.35 (Retained Earnings 874.4m / Total Assets 2.47b) |
| C: 0.06 (EBIT TTM 144.7m / Avg Total Assets 2.42b) |
| D: 0.53 (Book Value of Equity 846.6m / Total Liabilities 1.60b) |
| Altman-Z'' Score: 3.79 = AA |
Beneish M -3.10
| DSRI: 0.97 (Receivables 237.9m/247.0m, Revenue 2.83b/2.84b) |
| GMI: 1.03 (GM 46.79% / 48.28%) |
| AQI: 0.91 (AQ_t 0.22 / AQ_t-1 0.24) |
| SGI: 1.00 (Revenue 2.83b / 2.84b) |
| TATA: -0.03 (NI 89.1m - CFO 151.2m) / TA 2.47b) |
| Beneish M-Score: -3.10 (Cap -4..+1) = AA |
What is the price of CRI shares?
Over the past week, the price has changed by +6.30%, over one month by +4.93%, over three months by +19.36% and over the past year by -23.71%.
Is CRI a buy, sell or hold?
- StrongBuy: 0
- Buy: 0
- Hold: 3
- Sell: 2
- StrongSell: 1
What are the forecasts/targets for the CRI price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 33.4 | -9.2% |
| Analysts Target Price | 33.4 | -9.2% |
| ValueRay Target Price | 36.2 | -1.5% |
CRI Fundamental Data Overview February 05, 2026
P/E Forward = 16.3666
P/S = 0.4735
P/B = 1.5513
P/EG = 1.81
Revenue TTM = 2.83b USD
EBIT TTM = 144.7m USD
EBITDA TTM = 199.5m USD
Long Term Debt = 498.7m USD (from longTermDebt, last quarter)
Short Term Debt = 150.5m USD (from shortTermDebt, last quarter)
Debt = 1.18b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 994.2m USD (from netDebt column, last quarter)
Enterprise Value = 2.34b USD (1.34b + Debt 1.18b - CCE 184.2m)
Interest Coverage Ratio = 4.66 (Ebit TTM 144.7m / Interest Expense TTM 31.0m)
EV/FCF = 25.39x (Enterprise Value 2.34b / FCF TTM 92.0m)
FCF Yield = 3.94% (FCF TTM 92.0m / Enterprise Value 2.34b)
FCF Margin = 3.25% (FCF TTM 92.0m / Revenue TTM 2.83b)
Net Margin = 3.15% (Net Income TTM 89.1m / Revenue TTM 2.83b)
Gross Margin = 46.79% ((Revenue TTM 2.83b - Cost of Revenue TTM 1.51b) / Revenue TTM)
Gross Margin QoQ = 45.08% (prev 48.14%)
Tobins Q-Ratio = 0.95 (Enterprise Value 2.34b / Total Assets 2.47b)
Interest Expense / Debt = 0.61% (Interest Expense 7.17m / Debt 1.18b)
Taxrate = 21.85% (3.24m / 14.8m)
NOPAT = 113.1m (EBIT 144.7m * (1 - 21.85%))
Current Ratio = 2.26 (Total Current Assets 1.13b / Total Current Liabilities 501.7m)
Debt / Equity = 1.36 (Debt 1.18b / totalStockholderEquity, last quarter 864.6m)
Debt / EBITDA = 4.98 (Net Debt 994.2m / EBITDA 199.5m)
Debt / FCF = 10.81 (Net Debt 994.2m / FCF TTM 92.0m)
Total Stockholder Equity = 855.1m (last 4 quarters mean from totalStockholderEquity)
RoA = 3.68% (Net Income 89.1m / Total Assets 2.47b)
RoE = 10.42% (Net Income TTM 89.1m / Total Stockholder Equity 855.1m)
RoCE = 10.69% (EBIT 144.7m / Capital Employed (Equity 855.1m + L.T.Debt 498.7m))
RoIC = 8.35% (NOPAT 113.1m / Invested Capital 1.35b)
WACC = 5.94% (E(1.34b)/V(2.52b) * Re(10.74%) + D(1.18b)/V(2.52b) * Rd(0.61%) * (1-Tc(0.22)))
Discount Rate = 10.74% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.77%
[DCF Debug] Terminal Value 84.43% ; FCFF base≈166.2m ; Y1≈142.1m ; Y5≈109.9m
Fair Price DCF = 63.36 (EV 3.30b - Net Debt 994.2m = Equity 2.31b / Shares 36.4m; r=5.94% [WACC]; 5y FCF grow -17.63% → 2.90% )
EPS Correlation: -54.89 | EPS CAGR: -51.59% | SUE: -4.0 | # QB: 0
Revenue Correlation: -46.13 | Revenue CAGR: -8.61% | SUE: -1.26 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.32 | Chg30d=+0.077 | Revisions Net=+1 | Analysts=5
EPS next Year (2026-12-31): EPS=2.78 | Chg30d=+0.446 | Revisions Net=+3 | Growth EPS=-13.2% | Growth Revenue=-0.4%